Vivos Inc. is a radiation oncology medical device company. The Company has developed an Yttrium-90-based injectable Precision Radionuclide Therapy medical device to treat tumors in animals (IsoPet) and humans (RadioGel). Using the Companyâ€™s proprietary hydrogel technology, PRnT uses highly localized radiation to destroy cancerous tumors by placing a radioactive isotope directly inside the treatment area. The injection delivers therapeutic radiation from within the tumor without the entrance skin dose and associated side effects of treatment that characterize external-beam radiation therapy. This feature allows the safe delivery of higher doses needed for treating non-resectable and radiation-resistant cancers. University veterinary hospitals use the IsoPet Solutions division to demonstrate animal cancersâ€™ safety and therapeutic effectiveness. RadioGel is a hydrogel liquid containing tiny yttrium-90 phosphate microparticles that may be administered directly into a tumor.

Employees

Sector

Advanced Medical Equipment & Technology

More about the company

Quotes

Date	Price	Change	Volume
23/10/26	USD 0.0441	-4.42%	3,385,733
22/10/26	USD 0.0461	-0.77%	159,246
21/10/26	USD 0.0465	+0.43%	191,326
20/10/26	USD 0.0463	-3.08%	440,533
19/10/26	USD 0.0478	-2.51%	1,188,023

Real-time OTC Markets

More quotes

Market Closed - OTC Markets 02:29:24 05/06/26 am AEST			5-day change	1st Jan Change
0.0590 ^USD	-3.75%		+20.41%	-14.37%

07/10	Vivos Inc. announced that it has received $0.25 million in funding, from the other investors	CI
19/08	Vivos Inc Receives Authorization From Atomic Energy Regulatory Board Of India For International Manufacturing Center	CI

Market Cap	21.8M 19.46M 17.98M 16.29M 30.49M 2.07B 30.99M 216M 85.66M 1.08B 81.8M 80.06M 3.42B	P/E 2024	-16.2x	P/E 2025	-10.2x
Enterprise Value	20.35M 18.17M 16.79M 15.21M 28.47M 1.93B 28.94M 202M 79.99M 1.01B 76.38M 74.75M 3.19B	EV / Sales 2024	1,724x	EV / Sales 2025	438x
Free-Float	95.44%	Yield 2024 *	-	Yield 2025	-

07/10	Vivos Inc. announced that it has received $0.25 million in funding, from the other investors	CI
19/08	Vivos Inc Receives Authorization From Atomic Energy Regulatory Board Of India For International Manufacturing Center	CI
19/08	Vivos Announces First ISOPET Shipments from APEL, Richland, WA	CI
13/08	Vivos Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2026	CI
28/07	Vivos Inc. Receives FDA Approval for Feasibility Investigational Device Exemption Application and Provides Update on Precision Radionuclide Therapy Clinical Trials and Product Pipeline	CI
07/07	Vivos Inc. Receives U.S. FDA Approval for Investigational Device Exemption to Initiate Human Clinical Feasibility Study for RadioGel Precision Radionuclide Therapy	CI
12/06	Vivos Inc. Receives Washington State Radioactive Materials License for Isopet Manufacturing	CI
05/06	Vivos Inc. Submits Early Feasibility Investigational Device Exemption Application to FDA for Radiogel Precision Radionuclide Therapy	CI
15/05	Vivos Inc. Reports Earnings Results for the First Quarter Ended March 31, 2026	CI
31/03	Vivos Inc. Reports Earnings Results for the Full Year Ended December 31, 2025	CI
31/03	Vivos Inc. Auditor Raises 'Going Concern' Doubt	CI
18/02	Vivos Inc. Diversifies Manufacturing Base with Planned U.S. and International Production Sites	CI
11/02	Vivos Inc. Announces Significant Progress Toward FDA Investigational Device Exemption Submission for RadioGel Precision Radionuclide Therapy	CI

03/09	Vivos Inc. Announces Peer-Reviewed Publication Characterizing PrecisionGel™ Polymer Platform in Elsevier Journal of Drug Delivery Science and Technology	AQ
18/08	Vivos Inc. Achieves Two Major Operational Milestones: First IsoPet® Shipments from New U.S. Production Facility and Authorization from India’s Nuclear Regulatory Authority for International Manufacturing Center	AQ
27/07	Vivos Inc. (OTCQB: RDGL) Reports Second Quarter 2026 Progress and Corporate Update	AQ
06/07	Vivos Inc. (OTCQB: RDGL) Receives U.S. FDA Approval for Investigational Device Exemption (IDE) to Initiate Human Clinical Feasibility Study for RadioGel® Precision Radionuclide Therapy™	AQ
11/06	Vivos Inc. Announces Receipt of Washington State Radioactive Materials License for IsoPet® Manufacturing	AQ

Vivos Inc. Stock

Stocks

RDGL

US92858K2042

Advanced Medical Equipment & Technology

Valuation: Vivos Inc.

Chart: Vivos Inc.

Latest news: Vivos Inc.

Analysts' recommendations: Vivos Inc.

Press Releases: Vivos Inc.

Quotes and Performance

Price Extremes

Managers and Directors: Vivos Inc.

Latest insider transactions

Medical Imaging Systems

Financials

Company Profile

Quotes

1 day	-3.75%
1 week	+20.41%
Current month	+18.00%
1 month	+28.26%
3 months	+0.51%
6 months	-17.48%
Current year	-14.37%

1 week	0.04	0.06
1 month	0.04	0.06
Current year	0.04	0.12
1 year	0.04	0.12
3 years	0.04	0.26
5 years	0.04	0.26
10 years	0.01	1.92

Manager	Title	Age	Since
Michael Korenko CEO	Chief Executive Officer	79	14/12/2016
Brad Weeks PSD	President	44	15/09/2025
Michael Pollack DFI	Director of Finance/CFO	59	01/12/2018

Director	Title	Age	Since
Carlton Cadwell CHM	Chairman	81	14/12/2016
Michael Korenko BRD	Director/Board Member	79	02/08/2017

Date	Insider	Type	Main position	Quantity	% Market Cap.
7/10/26	Carlton Cadwell	Issuer sale	Chairman	-385,302	100.0000%
30/9/26	Michael Korenko	Buy	Chief Executive Officer	200,000	0.0405%
16/9/26	Brad Weeks	Buy	Chairperson	25,550	0.0052%

Add to a list 0 selected To use this feature you must be a member Log in Sign up	Change	5-day change	1-year change	3-year change	Capi.($)
VIVOS INC.	-3.75%	+20.41%	-26.25%	-2.48%	21.8M
THERMO FISHER SCIENTIFIC, INC.	-0.40%	-2.34%	+17.82%	+45.91%	249B
DANAHER CORPORATION	+0.33%	+0.64%	+3.49%	+12.96%	162B
INTUITIVE SURGICAL, INC.	+1.90%	+6.00%	-17.96%	+65.92%	157B
BOSTON SCIENTIFIC CORPORATION	-0.70%	+2.93%	-55.38%	-8.86%	66.22B
VEEVA SYSTEMS INC.	+0.15%	+4.09%	+10.82%	+65.55%	52.3B
SIEMENS HEALTHINEERS AG	+0.24%	+0.99%	-15.19%	-10.88%	52.18B
EDWARDS LIFESCIENCES CORPORATION	-1.13%	+2.85%	+16.39%	+28.99%	51.34B
AGILENT TECHNOLOGIES, INC.	-0.47%	+0.06%	+17.37%	+58.29%	48.79B
WATERS CORPORATION	-0.42%	+3.83%	+27.55%	+77.45%	44.57B
Average	-0.42%	+2.04%	-2.13%	+33.29%	88.35B
Weighted average by Cap.	+0.14%	+1.50%	+1.37%	+38.41%

	2024	2025
Net sales	28K 25K 23.09K 20.93K 39.16K 2.66M 39.8K 278K 110K 1.39M 105K 103K 4.39M	68.38K 61.06K 56.41K 51.12K 95.64K 6.49M 97.22K 679K 269K 3.4M 257K 251K 10.72M
Net income	-2.91M -2.6M -2.4M -2.18M -4.07M -276M -4.14M -28.89M -11.44M -145M -10.92M -10.69M -456M	-3.07M -2.74M -2.53M -2.29M -4.29M -291M -4.36M -30.44M -12.05M -152M -11.51M -11.26M -481M
Net Debt	-2.21M -1.98M -1.83M -1.65M -3.09M -210M -3.15M -21.96M -8.7M -110M -8.3M -8.13M -347M	-1.44M -1.29M -1.19M -1.08M -2.02M -137M -2.05M -14.34M -5.68M -71.83M -5.42M -5.3M -226M